{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T16:38:28Z","timestamp":1791650308344,"version":"4.3.4"},"reference-count":28,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T00:00:00Z","timestamp":1756857600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Brazilian Journal of Infectious Diseases"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.bjid.2025.104578","type":"journal-article","created":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T03:28:18Z","timestamp":1758598098000},"page":"104578","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Effectiveness of simplifying antiretroviral therapy to maintain viral suppression and improve bone and renal health: comparing simplified and non-simplified therapy"],"prefix":"10.1016","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6621-8497","authenticated-orcid":false,"given":"Juliana Olsen","family":"Rodrigues","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2187-4722","authenticated-orcid":false,"given":"Alexandre Naime","family":"Barbosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie Valentini Ferreira","family":"Proen\u00e7a","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lenice Ros\u00e1rio","family":"de Souza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bjid.2025.104578_bib0001","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.3201\/eid2706.210284","article-title":"Reflections on 40-years of AIDS","volume":"27","author":"De Cock","year":"2021","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.bjid.2025.104578_bib0002","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1097\/COH.0000000000000761","article-title":"Update on treatment as prevention of HIV illness, death, and transmission: sub-Saharan Africa HIV financing and progress towards the 95-95-95 target","volume":"17","author":"Gupta","year":"2022","journal-title":"Curr Opin HIV AIDS"},{"key":"10.1016\/j.bjid.2025.104578_bib0003","doi-asserted-by":"crossref","DOI":"10.7448\/IAS.20.01.21678","article-title":"Dolutegravir-lamivudine as initial therapy in HIV-1 infected, ARV-naive patients, 48-week results of the PADDLE (Pilot Antiretroviral Design with Dolutegravir Lamivudine) study","volume":"20","author":"Cahn","year":"2017","journal-title":"J Int AIDS Soc"},{"key":"10.1016\/j.bjid.2025.104578_bib0004","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11904-019-00474-1","article-title":"Bone update: is it still an issue without tenofovir disoproxil fumarate","volume":"17","author":"Shiau","year":"2020","journal-title":"Curr HIV\/AIDS Rep"},{"key":"10.1016\/j.bjid.2025.104578_bib0005","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1177\/0956462419848962","article-title":"Changes in renal, bone, lipid, and inflammation markers in HIV-1 patients after combination antiretroviral therapy simplification to dolutegravir monotherapy","volume":"30","author":"Wijting","year":"2019","journal-title":"Int J STD AIDS"},{"key":"10.1016\/j.bjid.2025.104578_bib0006","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1097\/QAI.0000000000000986","article-title":"Changes in kidney function and in the rate of tubular dysfunction after tenofovir withdrawal or continuation in HIV-infected patients","volume":"72","author":"Casado","year":"2016","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.bjid.2025.104578_bib0007","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.ijid.2019.03.034","article-title":"Lipid profile and renal safety of tenofovir disoproxil fumarate-based anti-retroviral therapy in HIV-infected Chinese patients","volume":"83","author":"Yang","year":"2019","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.bjid.2025.104578_bib0008","doi-asserted-by":"crossref","DOI":"10.1177\/2325958219867325","article-title":"Optimizing antiretroviral therapy in treatment-experienced patients living with HIV: a critical review of switch and simplification strategies. An opinion of the HIV Practice and Research Network of the American College of Clinical Pharmacy","volume":"18","author":"Chastain","year":"2019","journal-title":"J Int Assoc Provid AIDS Care"},{"key":"10.1016\/j.bjid.2025.104578_bib0009","series-title":"Brasil: Minist\u00e9rio da Sa\u00fade","year":"2018"},{"key":"10.1016\/j.bjid.2025.104578_bib0010","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1007\/s40264-018-0665-z","article-title":"Osteoporosis-related fractures in HIV-infected patients receiving long-term tenofovir disoproxil fumarate: an observational cohort study","volume":"41","author":"Komatsu","year":"2018","journal-title":"Drug Saf"},{"key":"10.1016\/j.bjid.2025.104578_bib0011","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1097\/QAD.0b013e32835192ae","article-title":"Osteoporotic fracture risk associated with cumulative exposure to tenofovir and other antiretroviral agents","volume":"26","author":"Bedimo","year":"2012","journal-title":"AIDS"},{"key":"10.1016\/j.bjid.2025.104578_bib0012","year":"2021","journal-title":"Brasil"},{"key":"10.1016\/j.bjid.2025.104578_bib0013","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration). A new equation to estimate glomerular filtration rate","volume":"150","author":"Levey","year":"2009","journal-title":"Ann Intern Med"},{"issue":"1","key":"10.1016\/j.bjid.2025.104578_bib0014","first-page":"1","article-title":"Kidney Disease: improving global outcomes (KDIGO) CKD work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic Kidney disease","volume":"3","year":"2013","journal-title":"Kidney Int Suppl"},{"key":"10.1016\/j.bjid.2025.104578_bib0015","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1590\/S0004-27302009000100016","article-title":"2008 Official positions of the Brazilian Society for Clinical Densitometry \u2013 SBDens","volume":"53","author":"Brand\u00e3o","year":"2009","journal-title":"Arq Bras Endocrinol Metab"},{"key":"10.1016\/j.bjid.2025.104578_bib0016","doi-asserted-by":"crossref","first-page":"60","DOI":"10.29245\/2578-3009\/2018\/1.1120","article-title":"Dolutegravir plus lamivudine as simplification dual therapy in virologically suppressed HIV-1 infected subjects","volume":"2","author":"Comi","year":"2018","journal-title":"J Immunol Sci"},{"key":"10.1016\/j.bjid.2025.104578_bib0017","series-title":"9th IAS Conference on HIV Science","first-page":"23","article-title":"Dual regimen with dolutegravir and lamivudine maintains virologic suppression even in heavily treatment experienced HIV-infected patients: 96 weeks results from maintenance DOLULAM study (abstract 2755)","author":"Reynes","year":"2017"},{"key":"10.1016\/j.bjid.2025.104578_bib0018","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1186\/s12879-017-2311-2","article-title":"Lamivudine\/dolutegravir dual therapy in HIV-infected, virologically suppressed patients","volume":"17","author":"Maggiolo","year":"2017","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.bjid.2025.104578_bib0019","series-title":"16th European AIDS conference. Milan","first-page":"25","article-title":"Multicenter study of the effectiveness and safety of a dual therapy with dolutegravir plus lamivudine in treatment-experienced HIV-patients. (Abstract PE 9\/68)","author":"Hidalgo-Tenorio","year":"2017"},{"key":"10.1016\/j.bjid.2025.104578_bib0020","series-title":"16th European AIDS conference. Milan","first-page":"25","article-title":"Real-life experience of dolutegravir and lamivudine dual therapy as a switching regimen in HIV-TR cohort. (abstract PE 9\/12)","author":"Yagci Caglayik","year":"2017"},{"key":"10.1016\/j.bjid.2025.104578_bib0021","doi-asserted-by":"crossref","DOI":"10.7448\/IAS.17.4.19817","article-title":"Switching to lamivudine plus darunavir\/r dual therapy in a cohort of treatment-experienced HIV-positive patients: the experience of an Italian centre","volume":"17","author":"Borghetti","year":"2014","journal-title":"J Int AIDS Soc"},{"key":"10.1016\/j.bjid.2025.104578_bib0022","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1097\/MNH.0000000000000392","article-title":"Potential kidney toxicity from the antiviral drug tenofovir: new indications, new formulations, and a new prodrug","volume":"27","author":"Chan","year":"2018","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"10.1016\/j.bjid.2025.104578_bib0023","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1007\/s11096-015-0132-1","article-title":"Incidence and risk factors for tenofovir-associated renal toxicity in HIV-infected patients","volume":"37","author":"Quesada","year":"2015","journal-title":"Int J Clin Pharm"},{"key":"10.1016\/j.bjid.2025.104578_bib0024","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1089\/apc.2016.0286","article-title":"Effect of tenofovir disoproxil fumarate on incidence of chronic kidney disease and rate of estimated glomerular filtration rate decrement in HIV-1-infected treatment-na\u00efve Asian patients: results from 12-year observational cohort","volume":"31","author":"Suzuki","year":"2017","journal-title":"AIDS Patient Care STDS"},{"key":"10.1016\/j.bjid.2025.104578_bib0025","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1097\/QAI.0000000000002275","article-title":"Durable efficacy of dolutegravir plus lamivudine in antiretroviral treatment-naive adults with HIV-1 infection: 96-week results from the GEMINI-1 and GEMINI-2 randomized clinical trials","volume":"83","author":"Cahn","year":"2020","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.bjid.2025.104578_bib0026","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/4380845","article-title":"Prospective study to assess progression of renal markers after interruption of tenofovir due to nephrotoxicity","author":"Bonjoch","year":"2016","journal-title":"Biomed Res Int"},{"key":"10.1016\/j.bjid.2025.104578_bib0027","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1186\/s12879-017-2311-2","article-title":"Mussini, Lamivudine\/dolutegravir dual therapy in HIV-infected, virologically suppressed patients","volume":"17","author":"Maggiolo","year":"2017","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.bjid.2025.104578_bib0028","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1097\/QAD.0000000000001725","article-title":"202094 Sub-Study Investigators. Switch from tenofovir disoproxil fumarate combination to dolutegravir with rilpivirine improves parameters of bone health","volume":"32","author":"McComsey","year":"2018","journal-title":"AIDS"}],"container-title":["The Brazilian Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1413867025000790?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1413867025000790?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T21:30:00Z","timestamp":1764624600000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1413867025000790"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":28,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S1413867025000790"],"URL":"https:\/\/doi.org\/10.1016\/j.bjid.2025.104578","relation":{},"ISSN":["1413-8670"],"issn-type":[{"value":"1413-8670","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effectiveness of simplifying antiretroviral therapy to maintain viral suppression and improve bone and renal health: comparing simplified and non-simplified therapy","name":"articletitle","label":"Article Title"},{"value":"The Brazilian Journal of Infectious Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bjid.2025.104578","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Sociedade Brasileira de Infectologia. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}],"article-number":"104578"}}